TY - JOUR
T1 - Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African Cohort Study
AU - the AFRICOS Study Group
AU - Bahemana, Emmanuel
AU - Esber, Allahna
AU - Dear, Nicole
AU - Ganesan, Kavitha
AU - Parikh, Ajay
AU - Reed, Domonique
AU - Maganga, Lucas
AU - Khamadi, Samoel
AU - Mizinduko, Mucho
AU - Lwilla, Anange
AU - Mkondoo, Dorothy
AU - Mwaisanga, Gwamaka
AU - Somi, Nancy
AU - Owouth, John
AU - Maswai, Jonah
AU - Kiweewa, Francis
AU - Iroezindu, Michael
AU - Ake, Julie A.
AU - Crowell, Trevor A.
AU - Valcour, Victor G.
AU - Polyak, Christina S.
AU - Hern, J.
AU - Duff, E.
AU - Reynolds, A.
AU - Bartolanzo, D.
AU - Song, K.
AU - Milazzo, M.
AU - Francisco, L.
AU - Schech, S.
AU - Golway, A.
AU - Mebrahtu, T.
AU - Lee, E.
AU - Bohince, K.
AU - Hamm, T.
AU - Lombardi, K.
AU - Imbach, M.
AU - Eller, L.
AU - Peel, S.
AU - Malia, J.
AU - Kroidl, A.
AU - Kroidl, I.
AU - Geldmacher, C.
AU - Kafeero, C.
AU - Nambuya, A.
AU - Tegamanyi, J.
AU - Birungi, H.
AU - Mugagga, O.
AU - Nassali, G.
AU - Wangiri, P.
AU - Nantabo, M.
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - Introduction: With increased use of antiretroviral therapy (ART), HIV mortality rates are declining and people living with HIV (PLWH) are surviving longer. We characterized CD4 recovery and viral suppression among adults aged < 50 and ≥ 50 years living with HIV who initiated ART in the African Cohort Study (AFRICOS). Methods: Beginning in January 2013, PLWH at twelve clinics in Kenya, Uganda, Tanzania and Nigeria underwent medical history review, CD4 and viral load testing as part of the ongoing African Cohort Study (AFRICOS). ART-naïve PLWH who initiated ART within 30 days of enrollment and had at least one year of follow-up were included in these analyses. To compare ART response in participants < 50 years and ≥ 50 years old, changes in CD4 count and viral load suppression after ART initiation were examined at different time points using linear and binomial regression with generalized estimating equations. Variables for time since ART initiation and the interaction between age group and time on ART were included in the model to evaluate longitudinal changes in CD4 recovery and viral suppression by age. Results: Between January 2013 and September 2019, 2918 PLHV were enrolled in the cohort. Of these, 443 were ART naïve and initiated on ART within 30 days of enrollment, with 90% (n = 399) aged < 50 years old at ART initiation. At ART initiation, participants aged 50 and older had a higher median CD4 count compared to participants younger than 50 years of age although it did not reach statistical significance (306 cells/mm3, IQR:130–547 vs. 277cells/mm3, IQR: 132–437). In adjusted models examining CD4 recovery and viral suppression there were no significant differences by age group over time. By the end of follow-up viral suppression was high among both groups of adults (96% of adults ≥ 50 years old and 92% of adults < 50 years old). Conclusion: This study found no difference in long-term CD4 recovery or viral suppression by age at ART initiation. We found that particularly among younger adults participants had lower median CD4 counts at ART initiation, suggesting the importance of identifying and putting this population on treatment earlier in the disease course.
AB - Introduction: With increased use of antiretroviral therapy (ART), HIV mortality rates are declining and people living with HIV (PLWH) are surviving longer. We characterized CD4 recovery and viral suppression among adults aged < 50 and ≥ 50 years living with HIV who initiated ART in the African Cohort Study (AFRICOS). Methods: Beginning in January 2013, PLWH at twelve clinics in Kenya, Uganda, Tanzania and Nigeria underwent medical history review, CD4 and viral load testing as part of the ongoing African Cohort Study (AFRICOS). ART-naïve PLWH who initiated ART within 30 days of enrollment and had at least one year of follow-up were included in these analyses. To compare ART response in participants < 50 years and ≥ 50 years old, changes in CD4 count and viral load suppression after ART initiation were examined at different time points using linear and binomial regression with generalized estimating equations. Variables for time since ART initiation and the interaction between age group and time on ART were included in the model to evaluate longitudinal changes in CD4 recovery and viral suppression by age. Results: Between January 2013 and September 2019, 2918 PLHV were enrolled in the cohort. Of these, 443 were ART naïve and initiated on ART within 30 days of enrollment, with 90% (n = 399) aged < 50 years old at ART initiation. At ART initiation, participants aged 50 and older had a higher median CD4 count compared to participants younger than 50 years of age although it did not reach statistical significance (306 cells/mm3, IQR:130–547 vs. 277cells/mm3, IQR: 132–437). In adjusted models examining CD4 recovery and viral suppression there were no significant differences by age group over time. By the end of follow-up viral suppression was high among both groups of adults (96% of adults ≥ 50 years old and 92% of adults < 50 years old). Conclusion: This study found no difference in long-term CD4 recovery or viral suppression by age at ART initiation. We found that particularly among younger adults participants had lower median CD4 counts at ART initiation, suggesting the importance of identifying and putting this population on treatment earlier in the disease course.
KW - Elders on antiretroviral drugs
KW - HIV and aging
KW - HIV treatment outcomes
KW - Sub-saharan Africa
UR - http://www.scopus.com/inward/record.url?scp=85095951368&partnerID=8YFLogxK
U2 - 10.1186/s12981-020-00323-x
DO - 10.1186/s12981-020-00323-x
M3 - Article
C2 - 33183355
AN - SCOPUS:85095951368
SN - 1742-6405
VL - 17
JO - AIDS Research and Therapy
JF - AIDS Research and Therapy
IS - 1
M1 - 66
ER -